Accelerated Emavusertib Approval Will Redefine Oncology Care
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
16 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$20.00
91.5% undervalued intrinsic discount21 Aug
US$1.71
1Y
-73.5%7D
-1.4%